Intravenous versus Nebulized Ceftazidime in Ventilated Piglets with and without Experimental Bronchopneumonia: Comparative Effects of Helium and Nitrogen
Tonnellier, Marc M.D.‡; Ferrari, Fabio M.D.†; Goldstein, Ivan M.D., Ph.D.‡; Sartorius, Alfonso M.D.§; Marquette, Charles-Hugo M.D., Ph.D.‖; Rouby, Jean-Jacques M.D., Ph.D.#
Background: Lung deposition of intravenous cephalosporins is low. The lung deposition of equivalent doses of ceftazidime administered either intravenously or by ultrasonic nebulization using either nitrogen–oxygen or helium–oxygen as the carrying gas of the aerosol was compared in ventilated piglets with and without experimental bronchopneumonia.
Methods: Five piglets with noninfected lungs and 5 piglets with Pseudomonas aeruginosa experimental bronchopneumonia received 33 mg/kg ceftazidime intravenously. Ten piglets with noninfected lungs and 10 others with experimental P. aeruginosa bronchopneumonia received 50 mg/kg ceftazidime by ultrasonic nebulization. In each group, the ventilator was operated in half of the animals with a 65%/35% helium–oxygen or nitrogen–oxygen mixture. Animals were killed, and multiple lung specimens were sampled for measuring ceftazidime lung tissue concentrations by high-performance liquid chromatography.
Results: As compared with intravenous administration, nebulization of ceftazidime significantly increased lung tissue concentrations (17 ± 13 vs. 383 ± 84 μg/g in noninfected piglets and 10 ± 3 vs. 129 ± 108 μg/g in piglets with experimental bronchopneumonia; P < 0.001). The use of a 65%/35% helium–oxygen mixture induced a 33% additional increase in lung tissue concentrations in noninfected piglets (576 ± 141 μg/g; P < 0.001) and no significant change in infected piglets (111 ± 104 μg/g).
Conclusion: Nebulization of ceftazidime induced a 5- to 30-fold increase in lung tissue concentrations as compared with intravenous administration. Using a helium–oxygen mixture as the carrying gas of the aerosol induced a substantial additional increase in lung deposition in noninfected piglets but not in piglets with experimental bronchopneumonia.
BECAUSE of the limited lung penetration of intravenously administered antibiotics, there is increasing interest in the inhalation route. However, available data on antibiotic lung deposition after aerosol are scarce, and nebulization is not considered a credible alternative to the intravenous route for treating ventilator-associated pneumonia. During mechanical ventilation, a significant part of the particles emitted by a nebulizer impacts the ventilatory circuits and the tracheobronchial tree before reaching the distal lung. The use of an ultrasonic nebulizer and the optimization of ventilatory settings during the nebulization period tend to limit extrapulmonary deposition and enhance distal lung penetration.1,2
We have recently demonstrated, in mechanically ventilated piglets with Escherichia coli
bronchopneumonia treated with amikacin, that substituting the intravenous route for the inhalation route allows a 10-fold increase in amikacin lung tissue concentrations.1–4
With such a concentration-dependent antibiotic, the high peak lung tissue concentrations resulting from nebulization were associated with rapid and impressive bacteria killing.2,4
As far as time-dependent antibiotics such as cephalosporins are concerned, tissue concentrations greater than minimal inhibitory concentrations should be permanently maintained at the site of infection, and intermittent high peak tissue concentrations may not be sufficient to provide a bactericidal effect. When minimal inhibitory concentrations increase, this goal cannot be achieved with the intravenous route. As experimentally observed with aminoglycosides, the nebulization of ceftazidime could be an attractive alternative to the intravenous route for treating ventilator-associated pneumonia caused by impaired sensitivity strains, and any means of improving lung deposition during nebulization may be of interest for obtaining and maintaining sufficiently high lung tissue concentrations.
A recent in vitro
study has shown that the aerosol delivered to an artificial lung during mechanical ventilation could be markedly improved by using a helium–oxygen mixture as the operating gas for ventilation.5
However, the effects of the helium–oxygen mixture on the in vivo
lung deposition of the aerosol was not directly investigated. The current study performed in mechanically ventilated piglets with noninfected lungs and experimental bronchopneumonia was conducted to compare lung deposition of equivalent doses of ceftazidime administered intravenously or by an ultrasonic nebulizer and to assess whether a helium–oxygen mixture could further increase lung tissue concentrations. In addition, extrapulmonary deposition and the size of particles were measured to compare the physical characteristics of the ceftazidime aerosol when the nebulizer was operated by the two different gas mixtures.
Materials and Methods
Thirty healthy bred domestic Largewhite-Landrace piglets, aged 3 months and weighting 20 ± 1 kg, were anesthetized and orotracheally intubated in the supine position with a 7.5 Hi-Lo Jet Mallinckrodt tube (Mallinckrodt Inc., Argyle, NY). The piglets were then turned in their physiologic position (prone position), ventilated using a Cesar ventilator (Taema, Antony, France), and monitored in the experimental intensive care unit.1–4,6–8
This study, including care of the animals involved, was conducted according to the official edict presented by the French Ministry of Agriculture (Paris, France) and the recommendations of the Helsinki Declaration. Thus, these experiments were conducted in an authorized laboratory and under the supervision of an authorized researcher (C.-H. M.). Arterial blood gas, tracheal airway pressure, and pressure–volume curve were measured as previously described.8,9
Bronchial Inoculation and Mechanical Ventilation
Fifteen piglets were inoculated with a suspension of Pseudomonas aeruginosa (identification by an API 32E kit; bioMérieux, Marcy l’Etoile, France). The initial suspension was diluted to a concentration of 106 colony-forming units/ml. A volume of 40 ml was selectively inoculated in each lower main bronchus using fiberoptic bronchoscopy. The inoculated piglets were then ventilated during 24 h with a fixed tidal volume of 15 ml/kg. Hemodynamic parameters, airway pressures, respiratory compliance, and blood gases were determined every 6 h. Throughout the protocol, the fraction of inspired oxygen was increased to maintain arterial oxygen tension above 80 mmHg.
As shown in figure 1
, an ultrasonic nebulizer (Atomisor MegaHertz; Diffusion Technique Française, Saint-Etienne, France) was placed in the inspiratory limb, 40 cm proximal to the Y piece.10,11
A filter with a pore size of less than 0.3 μm (Hygrobac; Mallinckrodt Medical, Mirandola, Italy) was placed on the expiratory limb to collect expired aerosolized particles. As previously recommended,11,12
experiments were performed without humidification of inspired gas, and aerosol delivery was optimized by using the following ventilatory settings: tidal volume of 15 ml/kg, constant inspiratory flow rate of 11 l/min, respiratory rate of 15 breaths/min, inspiratory:expiratory ratio of 1:1, and positive expiratory pressure of 5 cm H2
Because tidal volume is measured by a hot wire on the Cesar ventilator, a new calibration was performed when the 65%/35% helium–oxygen mixture was used. Using a pneumotachograph (Hans Rudolph Inc., Kansas City, MO) calibrated with a supersyringe containing a 65%/35% helium–oxygen mixture, the relation between set and delivered tidal volume was measured.
After the animals were killed, all ventilatory circuits, including the endotracheal tube and the expiratory filter, were washed separately in a fixed volume of distilled water to measure extrapulmonary deposition.1,2
In a separate in vitro
bench study, the volumetric mean diameter and the proportion of particles between 1 and 5 μm were measured with a laser velocimeter (Malvern Instrument, Worcestershire, UK) at the distal end of the endotracheal tube1,2
and expressed as the mean of three consecutive measurements performed with each operating gas.
Ten healthy piglets received a single 1-g dose of ceftazidime powder diluted in 15 ml sterile water through ultrasonic nebulization. A 65%/35% helium–oxygen mixture (noninfected helium–oxygen group; n = 5) or a 65%/35% nitrogen–oxygen mixture (noninfected nitrogen–oxygen group; n = 5) was used for ventilation during the period of nebulization. Five other piglets received a standard dose of ceftazidime (33 mg/kg) by intravenous infusion (noninfected intravenous group).
Twenty-four hours after the bacterial inoculation, 10 piglets with experimental bronchopneumonia received a single 1-g dose of ceftazidime by ultrasonic nebulization during ventilation with a 65%/35% helium–oxygen mixture (infected helium–oxygen group; n = 5) or with a 65%/35% nitrogen–oxygen mixture (infected nitrogen–oxygen group; n = 5), and 5 other piglets received a standard dose of ceftazidime (33 mg/kg) by intravenous infusion (infected intravenous group). Arterial blood gas, airway pressure, and static compliance were measured just before nebulization.
As previously described,1,2
the piglets were killed by exsanguination 15 min after completion of nebulization or intravenous infusion, and five lung samples per animal were collected from the upper, middle and lower lobes. Postmortem tissue samples were cryomixed in nitrogen, weighed, and homogenized, and ceftazidime concentrations were measured by high-performance liquid chromatography.13
Data were analyzed using Statview Software (SPSS, Inc., San Raphael, CA). Tissue ceftazidime concentrations were compared among the three groups using the Kruskal-Wallis one-way analysis of variance on ranks test followed by the Dunn post hoc comparison test. The correlation between the delivered dose and the lung concentration of ceftazidime was determined by linear regression (after the Kolmogorov-Smirnov test had confirmed that distribution of data were normal). A P value less than 0.05 was considered as significant. All data are expressed as mean ± SD.
When using the 65%/35% helium–oxygen mixture, delivered tidal volumes were always higher than set tidal volumes. The relation between delivered tidal volume and set tidal volume was linear, and a correction factor of 1.5 had to be applied to set tidal volume. To obtain a delivered tidal volume of 300 ml, the tidal volume had to be set at 200 ml on the ventilator.
The use of a helium–oxygen mixture did not modify the aerodynamic size distribution of particles: The volumetric mean diameter was 3.59 μm in the helium–oxygen group and 3.81 μm in the nitrogen–oxygen group, whereas the respirable range of particles, defined as the percentage of particles with aerodynamic size ranging between 1 and 5 μm, was 80% in the helium–oxygen group and 68% in the nitrogen–oxygen group. Positive end-expiratory pressure had no influence on the aerodynamic size distribution of particles. Similarly, the helium–oxygen mixture did not reduce the extrapulmonary deposition of the aerosol. Of the initial amount of ceftazidime placed in the nebulizer, 62 ± 7% (620 ± 70 mg) entered the tracheobronchial tree in the helium–oxygen group versus 50 ± 4% (500 ± 40 mg) in the nitrogen–oxygen group (not significant), a dose closely equivalent to the intravenous dose (660 ± 30 mg). In the helium–oxygen group, 11% of the dose was retained in the chamber of the nebulizer, 7% was retained in the inspiratory circuits, 6% was retained in the endotracheal tube, and 14% was retained in the expiratory filter. In the nitrogen–oxygen group, 15% of the dose was retained in the chamber of the nebulizer, 10% was retained in the inspiratory circuits, 10% was retained in the endotracheal tube, and 15% was retained in the expiratory filter.
As shown in table 1
, animals with experimental bronchopneumonia experienced a significant deterioration of gas exchange and respiratory mechanics as compared with noninfected piglets. The nature of the operating gas had no influence on arterial blood gas or respiratory mechanics. The aerosols, performed in 20 ± 7 min in all groups, were clinically well tolerated. No bronchospasm or blood gas alteration was observed.
As shown in figure 2
, in noninfected animals, ceftazidime lung tissue concentrations were 17 ± 13 μg/g after intravenous administration, 383 ± 84 μg/g after nitrogen–oxygen nebulization, and 576 ± 141 μg/g after helium–oxygen nebulization (P
< 0.001). The 33% increase in mean ceftazidime lung tissue concentrations observed when the ventilator was operated with the 65%/35% helium–oxygen mixture was highly significant (P
< 0.001). No significant relation was found between extrapulmonary deposition and ceftazidime lung tissue concentrations (P
In piglets with experimental bronchopneumonia (fig. 3
), ceftazidime lung tissue concentrations were 10 ± 3 μg/g after intravenous administration versus
129 ± 108 μg/g after nitrogen–oxygen nebulization (P
< 0.001). The mean ceftazidime lung tissue concentrations were not significantly different according to the gas mixture (129 ± 108 μg/g with nitrogen–oxygen vs.
111 ± 104 μg/g with helium–oxygen) and remained lower than in noninfected animals (P
In anesthetized and mechanically ventilated piglets with noninfected lungs, nebulization of ceftazidime resulted in a dramatic increase in lung tissue concentrations as compared with the concentrations observed after intravenous administration of an equivalent dose. In addition, when the ventilator was operated with a 65%/35% helium–oxygen mixture, an additional 33% increase in ceftazidime lung tissue concentration was observed. Because specimens removed from subpleural lung regions were composed of alveolar structures and distal bronchioles, these results clearly demonstrate that the helium–oxygen mixture markedly increased ceftazidime lung deposition and not only proximal airway deposition. Unfortunately, this beneficial effect was not observed in animals with infected lungs, thereby limiting the clinical relevance of the former finding.
Lung deposition of aerosolized particles during mechanical ventilation depends on several factors: the size of the particles; the extrapulmonary deposition into respiratory circuits; the physical characteristics of the gas flow reaching the distal lung; and the time allotted for sedimentation of particles within the bronchioloalveolar compartment and the alveolar aeration, which depends on the permeability of distal bronchioles. In the presence of normal distal lung aeration, particles between 3 and 5 μm have the highest probability of lung deposition, whereas particles larger than 5 μm generally impact the respiratory circuits, the endotracheal tube, or the proximal bronchi. During mechanical ventilation, antibiotic inhalation can be achieved by jet or ultrasonic nebulization. In the first technique, the gas operating the ventilator also operates the jet nebulizer: It generates particles through the Bernoulli effect and entrains the aerosol toward the distal lung.14
With an ultrasonic nebulizer, size distribution of particles results from the physical characteristics of the quartz vibrations and is not influenced by the inspiratory gas, which plays no role in aerosol generation. In the current study, as expected, the helium–oxygen mixture did not modify the mean volumetric diameter of particles. More surprisingly, the use of helium did not significantly reduce the aerosol extrapulmonary deposition. Previous laboratory studies have shown that decreasing the physical density of the carrying gas by replacing nitrogen by helium has opposite effects on aerosol performance: It reduces the efficiency of jet nebulizers by reducing the pressure decrease across the jet orifice5,14
but increases aerosol delivery of metered-dose inhalers by reducing flow turbulence within ventilatory circuits.5
The impaction of aerosolized particles on respiratory circuits and bronchial walls is markedly influenced by tidal volume, inspiratory flow rate, and humidification of inspired gas. Wall impaction is minimal with nonhumidified gas delivered at flow rates less than 40 l/min and increases with higher flows. In fact, wall impaction of particles markedly increases when the flow changes from laminar to turbulent. In the current study, the gas mixture was delivered at a low flow rate of 11 l/min required for providing a 300-ml (15-ml/kg) tidal volume to piglets. Very likely, turbulences of the nitrogen–oxygen flow within respiratory circuits and proximal bronchi were minimal with this flow rate, thereby limiting wall impaction. Using a helium–oxygen mixture did not further decrease gas flow turbulences and therefore did not further reduce extrapulmonary deposition as observed in previous in vitro
experiments using higher flows.5
In fact, the helium–oxygen mixture reduces extrapulmonary deposition of aerosolized particles only when the flow profile within respiratory circuit is changed from turbulent to laminar. Inspiratory flow rates greater than 40 l/min are commonly delivered for ventilation of patients with acute lung injury. Such high flows, by producing turbulences in the ventilator circuits and proximal airways, promote wall impaction of aerosolized particles when a nitrogen–oxygen mixture is used. The administration of a helium–oxygen mixture converts turbulent flows into laminar flows and thereby limits wall impaction and decreases extrapulmonary deposition.5
In the current study, such an effect was not observed because of the low inspiratory flow used in piglets. As a consequence, the 33% increase in ceftazidime deposition in noninfected animals observed with the 65%/35% helium–oxygen mixture was likely explained by helium-induced decreases in turbulences within distal bronchioles. In the distal bronchial tree, the reduction of the bronchiolar diameter and the great number of bronchiolar divisions physiologically produces turbulences even for low flows and promotes wall impaction of particles. Helium, by reducing gas density, reduces turbulences and promotes distal lung deposition, provided that bronchioles remain permeable.5
In the presence of ventilator-associated pneumonia, bronchiolitis results in bronchial plugs impairing downstream alveolar aeration.15
As a consequence, the 65%/35% helium–oxygen mixture did not provide additional lung deposition because the loss of alveolar aeration became predominant over flow turbulence. As far as clinical use is concerned, the efficiency of nebulized antibiotics is established to treat tracheobronchial colonization during cystic fibrosis16–20
or to prevent ventilator associated pneumonia.21
Even if they have been used successfully in several cases of severe bronchopneumonia caused by multiresistant P. aeruginosa
nebulized antibiotics are not recognized as an efficient treatment of ventilator-associated pneumonia. However, the potential advantages of nebulization over intravenous administration deserve to be outlined. As demonstrated in the current study, nebulization results in a marked increase in lung tissue concentrations. For a time-dependent antibiotic such as ceftazidime, concentrations equal to the minimal inhibitory concentration must be maintained over time at the site of the infection to kill bacteria. When the minimal inhibitory concentration increases, the weak lung deposition of intravenous ceftazidime associated with alterations of pharmacokinetics present in critically ill patients24
does not allow sufficient lung concentrations in most patients. The microorganism is then considered to be resistive to the antibiotic. The current study demonstrates that high ceftazidime lung tissue concentrations can be achieved in healthy and bronchopneumonic animals after ultrasonic nebulization. During bronchopneumonia, the use of a helium–oxygen mixture does not provide additional lung tissue deposition. It must be pointed out that only peak ceftazidime tissue concentrations were measured in the current study. Trough tissue concentrations are more relevant regarding time-dependent antibiotics, and additional studies are required to assess whether sufficient trough tissue concentrations can be maintained during the interval between two nebulized doses of ceftazidime.
The authors thank Arnold Dive and Michel Pottier (Technicians, University of Lille, France) for the preparation of the animals. The following members of the Experimental Intensive Care Unit Study Group participated in this study: Qin Lu, M.D. Ph.D. (Research Coordinator, Surgical Intensive Care Unit, Pierre Viars, Department of Anesthesiology), and Marie-Hélène Becquemin, M.D. (Pneumologist, Respiratory Physiology Department, La Pitié-Salpétrière Hospital, Paris, France); Kamel Louchahi, M.D. (Pharmacist), and Olivier Petitjean, M.D., Ph.D. (Professor of Pharmacology, Chairman of the Pharmacology Department, Avicennes Hospital, Bobigny, France); and Frédéric Wallet, M.D. (Bacteriologist, Bacteriology Laboratory, Calmette Hospital, Centre Hospitalier Régional Universitaire, Lille, France).
1. Goldstein I, Wallet F, Robert J, Becquemin MH, Marquette CH, Rouby JJ: Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 2002; 165:171–5
2. Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ: Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 2002; 166:1375–81
3. Ferrari F, Goldstein I, Nieszkowszka A, Elman M, Marquette CH, Rouby JJ: Lack of lung tissue and systemic accumulation after consecutive daily aerosols of amikacin in ventilated piglets with healthy lungs. Anesthesiology 2003; 98:1016–9
4. Elman M, Goldstein I, Marquette CH, Wallet F, Lenaour G, Rouby JJ: Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 2002; 97:199–206
5. Goode ML, Fink JB, Dhand R, Tobin MJ: Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am J Respir Crit Care Med 2001; 163:109–14
6. Marquette CH, Wermert D, Wallet F, Copin MC, Tonnel AB: Characterization of an animal model of ventilator-acquired pneumonia. Chest 1999; 115:200–9
7. Wermert D, Marquette CH, Copin MC, Wallet F, Fraticelli A, Ramon P, Tonnel AB: Influence of pulmonary bacteriology and histology on the yield of diagnostic procedures in ventilator-acquired pneumonia. Am J Respir Crit Care Med 1998; 158:139–47
8. Goldstein I, Bughalo MT, Marquette CH, Lenaour G, Lu Q, Rouby JJ: Mechanical ventilation-induced air-space enlargement during experimental pneumonia in piglets. Am J Respir Crit Care Med 2001; 163:958–64
9. Lu Q, Vieira SR, Richecoeur J, Puybasset L, Kalfon P, Coriat P, Rouby JJ: A simple automated method for measuring pressure-volume curves during mechanical ventilation. Am J Respir Crit Care Med 1999; 159:275–82
10. Harvey CJ, O’Doherty MJ, Page CJ, Thomas SH, Nunan TO, Treacher DF: Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. Eur Respir J 1997; 10:905–9
11. O’Doherty MJ, Thomas SH, Page CJ, Treacher DF, Nunan TO: Delivery of a nebulized aerosol to a lung model during mechanical ventilation: Effect of ventilator settings and nebulizer type, position, and volume of fill. Am Rev Respir Dis 1992; 146:383–8
12. Dhand R, Tobin MJ: Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med 1997; 156:3–10
13. Hanes SD, Herring VL, Wood GC: Alternative method for determination of ceftazidime in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998; 719:245–50
14. Hess DR, Acosta FL, Ritz RH, Kacmarek RM, Camargo CA Jr: The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Chest 1999; 115:184–9
15. Rouby JJ, Martin De Lassale E, Poete P, Nicolas MH, Bodin L, Jarlier V, Le Charpentier Y, Grosset J, Viars P: Nosocomial bronchopneumonia in the critically ill: Histologic and bacteriologic aspects. Am Rev Respir Dis 1992; 146:1059–66
16. Sermet-Gaudelus I, Le Cocguic Y, Ferroni A, Clairicia M, Barthe J, Delaunay JP, Brousse V, Lenoir G: Nebulized antibiotics in cystic fibrosis. Paediatr Drugs 2002; 4:455–67
17. de Gracia J, Maiz L, Prados C, Vendrell M, Baranda F, Escribano A, Gartner S, Lopez-Andreu JA, Martinez M, Martinez MT, Perez Frias J, Seculi JL, Sirvent J: Nebulized antibiotics in patients with cystic fibrosis. Med Clin (Barc) 2001; 117:233–7
18. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J 2000; 16:749–67
19. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W: Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995; 8:1594–604
20. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE: Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks. Thorax 1996; 51:364–8
21. Rouby JJ, Poete P, Martin de Lassale E, Nicolas MH, Bodin L, Jarlier V, Korinek AM, Viars P: Prevention of gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients: Histologic and bacteriologic study. Intensive Care Med 1994; 20:187–92
22. Hamer DH: Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162:328–30
23. Cole PJ: The role of nebulized antibiotics in treating serious respiratory infections. J Chemother 2001; 13:354–62
24. Gomez CM, Cordingly JJ, Palazzo MG: Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999; 43:1798–802
This article has been cited 16 time(s).
Expert Review of Anti-Infective TherapyDelivering antibiotics to the lungs of patients with ventilator-associated pneumonia: an updateExpert Review of Anti-Infective Therapy
Journal of Veterinary Pharmacology and TherapeuticsAn acute reversible experimental model of pneumonia in pigs: time-related histological and clinical signs changesJournal of Veterinary Pharmacology and Therapeutics
Intensive Care MedicineNebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosaIntensive Care Medicine
Intensive Care MedicineCeftazidime improves hemodynamics and oxygenation in ovine smoke inhalation injury and septic shock (vol 33, pg 1219, 2007)Intensive Care Medicine
European Respiratory JournalExperimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory responseEuropean Respiratory Journal
ChestExperimental severe Pseudomonas aeruginosa pneumonia and antibiotic therapy in piglets receiving mechanical ventilationChest
Revue Des Maladies RespiratoiresVentilator-associated pneumonia and chronic obstructive pulmonary diseaseRevue Des Maladies Respiratoires
The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia
Respiratory Care, 52(7):
Intensive Care MedicineComparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizersIntensive Care Medicine
European Respiratory JournalAnimal models of ventilator-associated pneumoniaEuropean Respiratory Journal
European Respiratory JournalEffects of glucocorticoids in ventilated piglets with severe pneumoniaEuropean Respiratory Journal
Seminars in Respiratory and Critical Care Medicine
Novel and innovative strategies to treat ventilator-associated pneumonia: Optimizing the duration of therapy and nebulizing antimicrobial agents
Seminars in Respiratory and Critical Care Medicine, 27(1):
Intensive Care MedicineNebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosaIntensive Care Medicine
Pediatric PulmonologySputum antibiotic concentrations: Implications for treatment of cystic fibrosis lung infectionPediatric Pulmonology
Critical Care MedicineAerosolized antibiotics are not a good idea—Don’t go with the flow: Premum Non Nocere!Critical Care Medicine
Critical Care MedicineAerosolized antibiotics for ventilator-associated tracheobronchitis: Let’s go with the flow!*Critical Care Medicine
© 2005 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.